Collaboration Revenue - Collaboration revenue was $1.1 million for the quarter ended September 30, 2024, compared to $2.5 ...

Completed Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) and remain on track to submit a BLA ...

the Company’s proprietary Senza5 TM platform unlocks the cytotoxic potential of engineered T cells and utilizes a five-day manufacturing process to maximize stemness, durability, and potency. By ...

Presented initial in vivo data for universal liver-targeted LNP and Wilson’s Disease program at ESGCT; initiated IND-enabling ...

selectively kills MTAP-deletion tumor cells that are present in approximately 15% of all tumor types; designed to avoid ...

M Therapeutics Inc. (4MTx), an early-stage biotechnology company developing treatments for neuropsychiatric and neurodegenerative diseases, today announced that the Company has been awarded a $120,000 ...

In today’s fast-paced world, maintaining optimal health and wellness has become more challenging than ever. People are ...

In today's demanding world, achieving optimal health and maintaining peak performance is more crucial than ever. Many ...

Good morning, and welcome to the Wave Life Sciences Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen only mode. As a reminder, this call is being ...

Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; ...